Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (201-210 of 294) with videos related to

Pageof 30
Sort By:
Cancers|February 15, 2022
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic LeukemiaDaniela V Wenge, Klaus Wethmar, Corinna A Klar, et al.
Investigational New Drugs|June 1, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Blood|July 23, 2013
IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCLHendrik Nogai, Sören-Sebastian Wenzel, Stephan Hailfinger, et al.
Investigational New Drugs|June 25, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Blood|December 14, 2004
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkMartin Dreyling, Georg Lenz, Eva Hoster, et al.
Hemasphere|January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell TherapyConrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
Cancers|November 26, 2022
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World ScenarioCarolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Genome Medicine|September 24, 2022
Intratumor heterogeneity and T cell exhaustion in primary CNS lymphomaMichael Heming, Svea Haessner, Jolien Wolbert, et al.
Pageof 30

Showing results (201-210 of 294) with videos related to

Sort By:
Pageof 30
Cancers|February 15, 2022
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic LeukemiaDaniela V Wenge, Klaus Wethmar, Corinna A Klar, et al.
Investigational New Drugs|June 1, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Blood|July 23, 2013
IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCLHendrik Nogai, Sören-Sebastian Wenzel, Stephan Hailfinger, et al.
Investigational New Drugs|June 25, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Blood|December 14, 2004
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkMartin Dreyling, Georg Lenz, Eva Hoster, et al.
Hemasphere|January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell TherapyConrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
Cancers|November 26, 2022
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World ScenarioCarolin Krekeler, Lea Reitnauer, Ulrike Bacher, et al.
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Genome Medicine|September 24, 2022
Intratumor heterogeneity and T cell exhaustion in primary CNS lymphomaMichael Heming, Svea Haessner, Jolien Wolbert, et al.
Pageof 30